This inventor holds 1 USPTO granted patent. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2008.
Company Filing History:
Years Active: 2008
Title: The Innovative Contributions of Denise Calaprice
Introduction
Denise Calaprice is a notable inventor based in Nyack, NY (US). She has made significant contributions to the field of medicine, particularly in the treatment of arthritis. Her innovative work has led to the development of a unique therapeutic approach that addresses various forms of arthritis.
Latest Patents
Denise Calaprice holds a patent for the "Use of an IL-1 antagonist for treating arthritis." This patent outlines methods for treating, inhibiting, or ameliorating arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile rheumatoid arthritis. The invention involves administering a therapeutic amount of an interleukin 1 (IL-1) antagonist to a human subject in need. The IL-1 antagonist is a fusion protein that includes specific binding portions and a multimerizing component, which enhances its effectiveness in treating arthritis.
Career Highlights
Calaprice is currently associated with Regeneron Pharmaceuticals, Inc., where she continues to advance her research and development efforts. Her work at Regeneron has positioned her as a key player in the pharmaceutical industry, contributing to innovative treatments that improve patient outcomes.
Collaborations
Throughout her career, Denise has collaborated with esteemed colleagues, including Scott Mellis and Neil E. Stahl. These collaborations have fostered a productive environment for innovation and have led to significant advancements in the field of arthritis treatment.
Conclusion
Denise Calaprice's contributions to the field of medicine, particularly through her patent on IL-1 antagonists, highlight her role as an influential inventor. Her work continues to impact the treatment of arthritis, showcasing the importance of innovation in healthcare.